




Toxicology Portfolio



CREDIBLE ASSAYS, INCREDIBLE RESULTS

As toxicologists, we are challenged to identify the adverse effects of a broad range of substances to protect people and the environment. It is critical that the standards and model organisms used in toxicological testing are reliable and authenticated. ATCC has the credible models that you need to perform standardized, reliable, and reproducible toxicology studies.

ATCC provides the cells, media, and reagents needed to explore renal, neural, airway, and skin toxicity for such applications as high-content screening, 3D culture, spheroid culture, permeability assays, metabolic stability and survival studies, transport activity measurement, and more. These toxicological tools can be used to identify responses to environmental insults or to screen pharmaceutical compounds.

CONTINUOUS CELL LINES

ATCC is home to over 4,000 continuous human and animal cell lines that can be used to refine traditional cell-based experiments or construct high-throughput assays, reducing the need for in vivo studies. Our continuous cell lines are always authenticated so you can rest assured that your in vitro models will deliver experimental success.

HUMAN PRIMARY CELLS

Human primary cells closely mimic the physiological state of cells in vivo and generate relevant data representing living systems. ATCC offers quality human primary cells matched with optimized growth media and supplements and a superior viability guarantee.

- Most cells expand to 15 population doublings
- Post-thaw viability greater than 70%
- All cells tested for positive and negative surface markers
- High cell purity guaranteed
- Additional donor information available

HTERT-IMMORTALIZED PRIMARY CELLS

The best of both worlds: ATCC hTERT-immortalized primary cells are a breakthrough in cell biology research. hTERT-immortalized primary cells do not senesce after a few passages, thereby reducing the need to repurchase and initiate growth of primary cells. Unlike continuous cell lines, these cells exhibit a stable karyotype and genotype and retain many of the physiological characteristics of the parental cells.

- In vivo biologies observed at high passage
- Average lifespan 5 times longer than primary cells
- Gene expression similar to the parental cell
- Zero donor (lot-to-lot) variability

CYTOTOXICITY

Find potential viability issues early with ATCC's wide array of biological solutions such as rodent and human cell lines, primary cells, and stem cells. We also offer the MTT Cell Proliferation Kit and XTT Cell Proliferation Kit to measure cell viability and growth.

Table 1: Human Primary Cells

ATCC® No.	Designation
PCS-100-013™	Human Umbilical Vein Endothelial Cells
PCS-201-010™	Normal Human Dermal Fibroblasts (Neonatal)
PCS-201-012™	Normal Human Dermal Fibroblasts (Adult)
PCS-400-010™	RPTEC Human Renal Proximal Tubular Epithelial Cells
PCS-500-010™	Human Umbilical Cord-derived Mesenchymal Stem Cells

Table 2: Cell Proliferation Assay Kits

ATCC® No.	Designation	Application
30-1010K™	MTT Cell Proliferation Assay Kit	Spectrophotometric measurement of cell viability and growth
30-1011K™	XTT Cell Proliferation Assay Kit	Measurement of cell viability and growth in tumor cell lines

ABSORPTION, DISTRIBUTION, METABOLISM, AND ELIMINATION (ADME) ASSAYS

Testing for absorption, distribution, metabolism, and elimination is crucial to moving your product to market. Get closer results to those observed in vivo and rule out possible toxicities faster using our entire ADME portfolio, featuring our hTERT-immortalized OAT1-, OCT2-, and OAT3-expressing kidney transporter cells. ATCC is here to support your preclinical research with our renal and hepatic models to be used in metabolic stability, metabolite identification, and drug-drug interaction assays.

Table 3: Hepatic cells

ATCC® No.	Designation	Product Description	Disease State
CRL-2254™	AML-12	<i>Mus musculus</i> ; liver; primary cells	Normal
CRL-2643™	ZFL [ZF-L]	<i>Danio rerio</i> ; liver; immortalized cell line	Normal
CRL-10741™	C3A [HepG2/C3A, derivative of Hep G2]	<i>Homo sapiens</i> ; liver; immortalized cell line	Hepatocellular carcinoma
CRL-11233™	THLE-3	<i>Homo sapiens</i> ; liver; immortalized cell line	Hepatocellular carcinoma
HB-8065™	Hep G2	<i>Homo sapiens</i> ; liver; immortalized cell line	Hepatocellular carcinoma

Table 4: Renal Cell Lines

ATCC® No.	Designation	Source Tissue
CRL-1573™	293 [HEK-293]	Embryonic kidney
CRL-2190™	HK-2	Kidney, cortex/proximal tubule
CRL-3213™	Phoenix-AMPHO	Kidney
CRL-11268™	293T/17 [HEK-293T/17]	Embryonic kidney
CRL-11268G-1™	OAT1 HEK 293T/17	Embryonic kidney stably overexpresses OAT1
HTB-44™	A-498	Kidney carcinoma
HTB-46™	Caki-1	Kidney; derived from metastatic site: skin

Table 5: Primary Renal Cells with Optimized Growth Media and Supplements

ATCC® No.	Designation	Growth kit	Basal medium
PCS-400-010™	Renal Proximal Tubule Epithelial Cells	Renal Epithelial Cell Growth Kit (ATCC® PCS-400-040™)	Renal Epithelial Cell Basal Medium (ATCC® PCS-400-030™)
PCS-400-011™	Renal Cortical Epithelial Cells		
PCS-400-012™	Renal Mixed Epithelial Cells		

Table 6: hTERT-Immortalized Primary Renal Cells, Genetically Modified Models, and Optimized Media and Growth Supplement

ATCC® No.	Designation	Growth kit	Basal medium
CRL-4031™	RPTEC/TERT1	hTERT-immortalized RPTEC Growth Kit (ATCC® ACS-4007™)	DMEM: F-12 Medium (ATCC® 30-2006™)
CRL-4031-OAT1™	RPTEC/TERT1 OAT1		
CRL-4031-OCT2™	RPTEC/TERT1 OCT2		
CRL-4031-OAT3™	RPTEC/TERT1 OAT3		




Figure 1: Kidney transporter over-expressing cell lines as compared to parental RPTEC/TERT1 cell lines. RPTEC/TERT1 SLC transporter cells were subjected to dome formation assay. Epithelial barrier formation is not compromised in OAT1-, OCT2-, and OAT3-expressing cell lines, as demonstrated by the formation of dome-like structures (arrows) caused by solute transport across an intact epithelial barrier.




Figure 2: Drug kinetic profiles of RPTEC/TERT1-OAT1 and RPTEC/TERT1-OCT2 transporter cells. (A) Solute uptake activity of RPTEC/TERT1-OAT1 cells was assessed using 6-CF as a substrate. 6-CF uptake increases with increasing 6-CF concentration in OAT1-expressing cells but not in parental RPTEC/TERT1 cells (n=3), indicating that the observed transport is due to OAT1 expression. (B) Solute uptake activity of RPTEC/TERT1-OCT2 cells was assessed by using EAM-1 as substrate. EAM-1 uptake increases with increasing amounts of EAM-1 in OCT2-expressing cells but not in parental RPTEC/TERT1 cells (n=3), indicating that the observed solute transport is due to OCT2 expression. (C) OAT1-expressing cells were exposed to increasing concentrations of the known OAT1 inhibitor novobiocin while 6-CF concentration and uptake time were held constant at 3 µM and 20 minutes (n=3). (D) OCT2-expressing cells were exposed to increasing concentrations of the known OCT2 inhibitor quinitin while EAM-1 concentration and uptake time were held constant at 5 µM and 20 minutes (n=3). The resulting inhibition curves indicate that OAT1 and OCT2 have physiologically relevant transport activity when overexpressed in RPTEC/TERT1 cells.

NEUROTOXICITY

Cells of the nervous system are well-specialized and rarely undergo mitosis once differentiated. ATCC offers many cell lines derived from neural tissues and neural progenitor cells that can be easily differentiated into those needed for neurotoxicity studied. Work with differentiating or terminally differentiated neurons, astrocytes, and oligodendrocytes sooner-yield experimental results faster.

Table 7: Human and Animal Neural Tissue-Derived Cell Lines

ATCC® No.	Designation	Comments
ACS-1018™	BT142 mut/-	Brain; oligoastrocytoma grade III
CCL-107™	C6	Brain, glial; glioma
CRL-1721™	PC-12	Adrenal; pheochromocytoma
CRL-2266™	SH-SY5Y	Bone marrow, epithelial; neuroblastoma
CRL-2927™	LUHMES	Brain, embryonic mesencephalon
CRL-2941™	S16	Sciatic nerve, epithelial
CRL-2943™	S16Y	Sciatic nerve, schwann cell
CRL-10742™	HCN-2	Cortical neuron; encephalitis

Table 8: Neural Progenitor Cells with Media Supplement Kits

ATCC® No.	Designation
ACS-3003™	NPC Growth Kit
ACS-3004™	NPC Dopaminergic Differentiation Kit
ACS-5001™	NPCs derived from ATCC-DYS0530 Parkinson's Disease (ACS-1013)
ACS-5003™	NPCs derived from ATCC-BXS0117 (ACS-1031)
ACS-5004™	NPCs derived from ATCC-BYS0112 (ACS-1026)
ACS-5005™	Neural Progenitor Cells derived from XCL-1 DCX-GFP
ACS-5006™	Neural Progenitor Cells derived from XCL-1 GFAP-Nanoluc®-Halotag®
ACS-5007™	Neural Progenitor Cells derived from XCL-1 MAP2-Nanoluc®-Halotag®




Figure 3: Dose response curves for cell viability of NPCs treated with paclitaxel, cisplatin, piperine, vincristine, chlorhexidine, amiodarone, and hydroxyurea for two days. Paclitaxel, vincristine, and amiodarone significantly decreased viability ($p < 0.01$) of NPCs ($n=3$, $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ vs. DMSO control, Student's T-test).

SKIN CORROSION, SENSITIZATION, AND IRRITATION TESTING

ATCC offers a wide selection of cell lines, primary cells, and hTERT-immortalized cells for modeling of the skin. In addition, we supply media and supplements that support cell culture conditions in the presence or absence of serum. These products can be utilized to create 3D skin models or used in basic assays that comply with OECD standards.

Table 9: Human Cell Lines

ATCC® No.	Designation	Species	Cell Type and Disease State
CRL-1872™	A375.S2	<i>Homo sapiens</i>	malignant melanoma
CRL-2309™	CCD 1106 KERTr	<i>Homo sapiens</i>	keratinocyte
CRL-2310™	CCD 1102 KERTr	<i>Homo sapiens</i>	keratinocyte; human papillomavirus 16
CRL-2404™	HEK001	<i>Homo sapiens</i>	keratinocyte
CRL-2500™	A7 [M2A7]	<i>Homo sapiens</i>	melanoma
CRL-3232™	VMM917	<i>Homo sapiens</i>	melanoma, Stage IV; malignant
CRL-9446™	CHL-1	<i>Homo sapiens</i>	melanoma
HTB-72™	SK-MEL-28	<i>Homo sapiens</i>	malignant melanoma

Table 10: Human Primary Epidermal Cells

Cell Type	Product Name	ATCC® No.	Growth Kit	Basal Media
Keratinocytes	Epidermal Keratinocytes; Adult	PCS-200-011™	Keratinocyte Growth Kit (ATCC® No. PCS-200-040™)	Dermal Cell Basal Medium (ATCC® No. PCS-200-030™)
Keratinocytes	Epidermal Keratinocytes; Neonatal Foreskin	PCS-200-010™	Keratinocyte Growth Kit (ATCC® No. PCS-200-040™)	Dermal Cell Basal Medium (ATCC® No. PCS-200-030™)
Melanocytes	Epidermal Melanocytes; Adult	PCS-200-013™	Melanocyte Growth Kit (ATCC® No. PCS-200-041™)	Dermal Cell Basal Medium (ATCC® No. PCS-200-030™)
Melanocytes	Epidermal Melanocytes; Neonatal Foreskin	PCS-200-012™	Adult Melanocyte Growth Kit (ATCC® No. PCS-200-042™)	Dermal Cell Basal Medium (ATCC® No. PCS-200-030™)
Fibroblasts	Dermal Fibroblasts; Adult	PCS-201-012™	Fibroblast Growth Kit, Serum-free (ATCC® No. PCS-201-040™) or Fibroblast Growth Kit, Low Serum (ATCC® No. PCS-201-041™)	Fibroblast Basal Medium (ATCC® No. PCS-201-030™)
Fibroblasts	Dermal Fibroblasts; Neonatal	PCS-201-010™	Fibroblast Growth Kit, Serum-free (ATCC® No. PCS-201-040™) or Fibroblast Growth Kit, Low Serum (ATCC® No. PCS-201-041™)	Fibroblast Basal Medium (ATCC® No. PCS-201-030™)
Fibroblasts	Dermal Fibroblasts; Neonatal, Mitomycin C-treated	PCS-201-011™	Fibroblast Growth Kit, Serum-free (ATCC® No. PCS-201-040™) or Fibroblast Growth Kit, Low Serum (ATCC® No. PCS-201-041™)	Fibroblast Basal Medium (ATCC® No. PCS-201-030™)

Table 11: hTERT-Immortalized Primary Cells

ATCC® No.	Designation	Tissue	Disease State
CRL-4001™	BJ-5ta	Foreskin, fibroblast	normal
CRL-4005™	TelCOFS02MA	Skin, fibroblast	cerebro-oculo-facio-skeletal syndrome
CRL-4048™	Ker-CT	Foreskin, keratinocyte	normal
CRL-4059™	hTERT-immortalized Dermal Melanocyte	Skin, female	normal
CRL-4064™	hTERT Neonatal Dermal Melanocyte	Skin, female	normal




Figure 4: Micrograph of hTERT-immortalized Primary Keratinocytes (Ker-CT) at 11 days post airlift. A) Phase contrast micrograph at 10x magnification. Panels B-E show keratinocytes stained with (B) DAPI, (C) anti-KRT14 antibodies, (D) anti-filaggrin antibodies, or (E) an overlay.




Figure 5: Treatment of skin models with 1% Triton X-100 to test the ability of these models to resist penetration. Ker-CT or primary keratinocytes with (A) collagen raft and (B) without collagen raft were treated with 1% Triton™ X-100 (Dow) at different durations. Viability was measured with MTT (ATCC® No. [30-1010K™](#)). Dashed lines indicate the IC50, which are within the Organization for Economic Co-operation Development (OECD) guidelines of 4-10 hours for functional human skin models.

GENOTOXICITY

In vitro genotoxicity testing is made easy with ATCC materials. We offer the cells and bacteria you need for OECD-validated assays such as the bacterial reverse mutation test (Ames test), the in vitro mammalian chromosomal aberration test, and the in vitro mammalian cell micronucleus test.

Table 12: Human and Animal Cell Lines

ATCC® No.	Designation	Species	Comments
CCL-61™	CHO-K1	<i>Cricetulus griseus</i>	epithelial-like ovary cell line
CCL-93™	V79-4	<i>Cricetulus griseus</i>	lung, fibroblast
CRL-1935™	CHL/IU [CHL-11]	<i>Cricetulus griseus</i>	lung, fibroblast, female, newborn
CRL-8015™	TK6	<i>Homo sapiens</i>	lymphoblast
CRL-9518™	L5178Y TK+/- Clone (3.7.2C)	<i>Mus musculus</i>	lymphoblast; lymphoma

Table 13: Bacteria

ATCC® No.	Species	Designation
BAA-2720™	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	LT2 TA98
BAA-2721™	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	LT2 TA100
BAA-2722™	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	LT2 TA102
29629™	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	TA1535
29630™	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium	TA1537
49979™	<i>Escherichia coli</i>	WP2 uvrA

RESPIRATORY TOXICITY

ATCC® offers primary airway epithelial cells, smooth muscle cells (SMCs), and fibroblasts, as well as growth media and media supplements for in vitro models to boost the scientific relevance of upper respiratory studies. Our materials make it simple to test for tissue variability, cytotoxicity, and more.

Table 14: Human Cell Lines

ATCC® No.	Designation	Comments
CCL-153™	HFL1	Lung
CCL-185™	A549	Lung
CRL-1848™	NCI-H292	Lung, mucoepidermoid pulmonary carcinoma
CRL-5826™	NCI-H226	Lung, squamous cell carcinoma, mesothelioma
CRL-9609™	BEAS-2B	Lung, bronchial
HTB-55™	Calu-3	Lung, epithelial, adenocarcinoma
HTB-174™	NCI-H441	Lung, papillary adenocarcinoma

Table 15: Human Primary Airway Cells; Normal

ATCC® No.	Designation	Growth kit	Basal medium
PCS-130-010™	Lung Smooth Muscle Cells	Vascular Smooth Muscle Cell Growth Kit (ATCC® PCS-100-042™)	Vascular Cell Basal Medium (ATCC® PCS-100-030™)
PCS-130-011™	Bronchial/Tracheal Smooth Muscle Cells		
PCS-201-013™	Lung Fibroblasts	Fibroblast Growth Kit, Low Serum (ATCC® PCS-201-041™)	Fibroblast Basal Medium (ATCC® PCS-201-030™)
PCS-301-010™	Small Airway Epithelial Cells		
PCS-300-010™	Bronchial/Tracheal Epithelial Cells	Bronchial Epithelial Cell Growth kit (ATCC® PCS-300-040™)	Airway Epithelial Cell Basal Medium (ATCC® PCS-300-030™)
PCS-300-015™	Primary Lobar Epithelial Cells		

Table 16: Human Primary Airway Cells; Disease

ATCC® No.	Designation	Growth kit	Basal medium
PCS-201-015™	Lung Fibroblasts; Asthma	Fibroblast Growth Kit, Low Serum (ATCC® PCS-201-041™)	Fibroblast Basal Medium (ATCC® PCS-201-030™)
PCS-201-016™	Lung Fibroblasts; Cystic Fibrosis		
PCS-201-017™	Lung Fibroblasts; COPD		
PCS-201-020™	Lung Fibroblast; Fibrosis		
PCS-300-011™	Bronchial/Tracheal Epithelial Cells; Asthma	Bronchial Epithelial Cell Growth kit (ATCC® PCS-300-040™)	Airway Epithelial Cell Basal Medium (ATCC® PCS-300-030™)
PCS-300-013™	Bronchial/Tracheal Epithelial Cells; COPD		
PCS-300-014™	Bronchial/Tracheal Epithelial Cells; Fibrosis		
PCS-301-011™	Small Airway Epithelial Cells; Asthma		
PCS-301-013™	Small Airway Epithelial Cells; COPD		
PCS-301-014™	Small Airway Epithelial Cells; Fibrosis		

Table 17: hTERT-Immortalized Primary Airway Cells

ATCC® No.	Designation	Comments
CRL-4011™	NuLi-1	Lung, epithelium; normal
CRL-4013™	CuFi-1	Lung, epithelial; cystic fibrosis
CRL-4015™	CuFi-4	Lung, bronchial; cystic fibrosis
CRL-4016™	CuFi-5	Lung, epithelial; cystic fibrosis
CRL-4017™	CuFi-6	Lung, bronchial; cystic fibrosis
CRL-4050™	HSAEC1-KT	Lung, small airway; normal
CRL-4051™	HBEC3-KT	Lung, bronchial; normal




Figure 6: Primary HBECS form differentiated airway epithelial structures in an air-liquid interface cell culture model. Primary bronchial/tracheal epithelial cells at 28 days post airlift, and then stained with A) H&E, indicating cilia (black arrows) and goblet cells. B) Cross sections of the cells reveal PAS/Alcian blue stained-vesicles (white arrows), which suggest mucus synthesis. These results have also been observed in primary small airway cells.




Figure 7: Differentiated primary respiratory epithelial cells secrete mucus. Small airway and bronchial/tracheal epithelial cells were grown in airlift 3D culture as in Figure 6. MUC5AC (an indicator of mucus secretion) was monitored via ELISA from the supernatant after a PBS wash or from the lysate of the cells. The observed expression and secretion of MUC5AC, coupled with the airway-type structures seen in Figure 6 suggests that primary airway cells can be used as an in vitro model of the respiratory lining.





Figure 8: Viability of primary and hTERT-immortalized primary lung fibroblasts treated with chlorhexidine (CHX). Fibroblasts were treated with low (1 µM) and high (10 µM) doses of CHX for 1 to 3 hours. After treatment, cells were washed, incubated with a resazurin-based reagent, and viability was assessed using a fluorescence plate reader. Data was normalized to untreated cells. Both (A) primary and (B) hTERT-immortalized fibroblasts respond to CHX in a dose- and time-dependent manner, indicating that hTERT-immortalized fibroblasts lend physiological relevance to toxicity testing.

IMMUNOTOXICITY

Immunotoxicity testing is a vital step to ensure the safety of a product, especially for medical devices. New in vitro methods can help identify immunosuppressants and immunostimulants as well as hypersensitivity and autoimmunity before you spend valuable time and resources on in vivo methods. ATCC offers high-quality cells that can be used for immunotoxicity tests.

Table 18: Human Cell Lines

ATCC® No.	Designation	Species	Cell Type and Disease State
CCL-246™	KG-1	<i>Homo sapiens</i>	Macrophage; acute myelogenous leukemia
CRL-1593.2™	U-937	<i>Homo sapiens</i>	Monocyte; histiocytic lymphoma
CRL-2407™	NK-92	<i>Homo sapiens</i>	Natural killer cell; malignant non-Hodgkin's lymphoma
TIB-71™	RAW 264.7	<i>Mus musculus</i>	Macrophage; Abelson murine leukemia virus-induced tumor
TIB-202™	THP-1	<i>Homo sapiens</i>	Monocyte; acute monocytic leukemia

Table 19: Human Primary Immune Cells

ATCC® No.	Designation	Availability
ACS-7010™	iPSC-derived Mesenchymal Stem Cells, BYS0112	Available
ACS-7020™	iPSC-derived CD34+ Cells, BXS0117	Available
ACS-7030™	iPSC-derived Monocytes, DYS0100	Available
PCS-800-010™	Peripheral Blood CD14+ Monocytes	Available
PCS-800-011™	Peripheral Blood Mononuclear Cells	Available
PCS-800-012™	Bone Marrow CD34+ Cells	Available
PCS-800-013™	Bone Marrow Mononuclear Cells	Available
PCS-800-014™	Cord Blood CD34+ Cells	Available
PCS-800-016™	Peripheral Blood CD4+ Helper T Cells	Available
PCS-800-017™	Peripheral Blood CD8+ Cytotoxic T Cells	Available
PCS-800-018™	Peripheral Blood CD19+ B Cells	Available
PCS-800-019™	Peripheral Blood CD56+ Natural Killer Cells	Available






Figure 9: iPSC-derived Monocytes (ATCC® [ACS-7030™](#)) can be used for conducting the monocyte activation test (MAT) for detecting endotoxins. iPSC-derived monocytes or PBMCs (ATCC® [PCS-800-011™](#)) were treated with the indicated concentrations of lipopolysaccharide (LPS), and secretion of the pro-inflammatory cytokine interleukin 6 (IL-6) was monitored. The concentration-dependent increase in IL-6 indicates the usefulness of iPSC-derived monocytes for developing cell-based endotoxin detection assays.


EXPLORE OUR FULL PORTFOLIO AT WWW.ATCC.ORG/TOX.



10801 University Boulevard
Manassas, Virginia 20110-2209

 703.365.2700

 703.365.2701

 sales@atcc.org

 www.atcc.org

TOX-092022-v15

©2022 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise. Triton™ is a trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow. NanoLuc® and Halotag® are registered trademarks of Promega Corporation.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services or to manufacture commercial products without prior ATCC written approval.

